B02 synergy with remdesivir. (A) Vero-E6 cells were infected with SARS-CoV-2 at MOI 0.05 and treated with 2 μM remdesivir, 10 μM B02, or a combination of 2 μM remdesivir and 10 μM B02 for 72h. CPE inhibition was measured by CTG assay. (B) Calu-3 cells were infected with SARS-CoV-2 at MOI 0.05 and treated with remdesivir at indicated concentrations in the presence or absence of 10 μM B02 for 96h. CPE inhibition was measured by CTG assay and was normalized to DMSO-treated wells. Data represent mean ± SD for n = 2 technical replicates.